Browsing by Author "Berbotto, Guillermo A."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group
    (2021) Gomez-Puerta, Jose A.; Pons-Estel, Guillermo J.; Quintana, Rosana; Nieto, Romina; Serrano Morales, Rosa M.; Harvey, Guillermina B.; Wojdyla, Daniel; Scolnik, Marina; Funes Soaje, Carmen; Alba Moreyra, Paula; Novatti, Elisa; Arizpe, Fernando; Berbotto, Guillermo A.; Gonzalez Lucero, Luciana; Porta, Sabrina; Perez, Nicolas; Rodriguez, Anabella M.; Appenzeller, Simone; de Oliveira e Silva Montadon, Ana Carolina; Monticielo, Odirlei Andre; Cavalcanti, Fernando S.; Ribeiro, Francinne Machado; Borba, Eduardo F.; dos Reis-Neto, Edgard Torres; Neira, Oscar; Miguel Chahuan, Jose; Mimica, Milena; Aroca Martinez, Gustavo; Tobon, Gabriel J.; Vasquez, Gloria; Quintana-Lopez, Gerardo; Moreno Alvarez, Mario J.; Angel Saavedra, Miguel; Perez Cristobal, Mario; Fragoso-Loyo, Hilda; Amezcua-Guerra, Luis M.; Gonzalez-Bello, Yelitza C.; Abud-Mendoza, Carlos; Esquivel-Valerio, Jorge A.; Duarte, Margarita; Acosta Colman, Isabel; Mora-Trujillo, Claudia; Reategui-Sokolova, Cristina; Calvo Quiroz, Armando A.; Munoz-Louis, Roberto; Cairoli, Ernesto; Rosas, Iliana; Rebella, Martin; Cardiel, Mario H.; Garcia de la Torre, Ignacio; Catoggio, Luis J.; Alarcon, Graciela S.; Pons-Estel, Bernardo A.
    Introduction: After more than 20 years of sustained work, the Latin American Group for the Study of Lupus (GLADEL) has made a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region. Methods: A new generation of "Lupus Investigators" in more than 40 centers throughout Latin America has been constituted in order to continue the legacy of the investigators of the original cohort and to launch a novel study of serum and urinary biomarkers in patients with systemic lupus erythematosus. Results: So far, we have recruited 807 patients and 631 controls from 42 Latin-American centers including 339 patients with SLE without renal involvement, 202 patients with SLE with prevalent but inactive renal disease, 176 patients with prevalent and active renal disease and 90 patients with incident lupus nephritis. Conclusions: The different methodological aspects of the GLADEL 2.0 cohort are discussed in this manuscript, including the challenges and difficulties of conducting such an ambitious project.
  • No Thumbnail Available
    Item
    Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort
    (2019) Pimentel-Quiroz, V. R.; Ugarte-Gil, M. F.; Harvey, G. B.; Wojdyla, D.; Pons-Estel, G. J.; Quintana, R.; Esposto, A.; Garcia, M. A.; Catoggio, L. J.; Cardiel, M. H.; Barile, L. A.; Amigo, M-C; Sato, E., I; Bonfa, E.; Borba, E.; Lavras Costallat, L. T.; Neira, O. J.; Massardo, L.; Guibert-Toledano, M.; Chacon-Diaz, R.; Alarcon, G. S.; Pons-Estel, B. A.; Soriano, Enrique R.; Ceballos Recalde, Maria Flavia; Velozo, Edson; Manni, Jorge A.; Grimaudo, Sebastian; Sarano, Judith; Maldonado-Cocco, Jose A.; Arriola, Maria S.; Gomez, Graciela; Ines Marcos, Ana; Carlos Marcos, Juan; Scherbarth, Hugo R.; Lopez, Jorge A.; Motta, Estela L.; Drenkard, Cristina; Gamron, Susana; Buliubasich, Sandra; Onetti, Laura; Caeiro, Francisco; Alvarellos, Alejandro; Saurit, Veronica; Gentiletti, Silvana; Quagliatto, Norberto; Gentiletti, Alberto A.; Machado, Daniel; Abdala, Marcelo; Palatnik, Simon; Berbotto, Guillermo A.; Battagliotti, Carlos A.; Souza, Alexandre Wagner S.; Bertolo, Manoel Barros; Coimbra, Ibsen Bellini; Tavares Brenol, Joao C.; Monticielo, Odirlei; Xavier, Ricardo; Cavalcanti, Fernando de Souza; Branco Duarte, Angela Luzia; Lopes Marques, Claudia Diniz; da Silva, Nilzio Antonio; de O e Silva, Ana Carolina; Pacheco, Tatiana Ferracine; Fernando Molina-Restrepo, Jose; Molina-Lopez, Javier; Vasquez, Gloria; Ramirez, Luis A.; Uribe, Oscar; Iglesias-Gamarra, Antonio; Iglesias-Rodriguez, Antonio; Egea-Bermejo, Eduardo; Guzman-Moreno, Renato A.; Restrepo-Suarez, Jose F.; Alberto Reyes-Llerena, Gil; Hernandez-Martinez, Alfredo; Jacobelli, Sergio; Guzman, Leonardo R.; Garcia-Kutzbach, Abraham; Castellanos, Claudia; Cajas, Erwin; Pascual-Ramos, Virginia; Silveira, Luis H.; Garcia De La Torre, Ignacio; Orozco-Barocio, Gerardo; Estrada-Contreras, Magali L.; Sauza del Pozo, Maria Josefina; Aranda Baca, Laura E.; Urenda Quezada, Adelfia; Huerta-Yanez, Guillermo F.; Acevedo-Vazquez, Eduardo M.; Luis Alfaro-Lozano, Jose; Cucho-Venegas, Jorge M.; Ines Segami, Maria; Chung, Cecilia P.; Alva-Linares, Magaly; Abadi, Isaac; Rangel, Neriza; Al Snih Al Snih, Soham; Esteva-Spinetti, Maria H.; Vivas, Jorge
    Aim The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). Methods A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. Results Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20-37) years and 47.8 (17.9-68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48-0.99; p = 0.0440) was protective, while doses of prednisone >15 and <= 60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69-10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35-16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10-2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01-1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11-1.34; p < 0.0001) were predictive factors of serious infections. Conclusions Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.
  • Thumbnail Image
    Item
    Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
    (2017) Ugarte Gil, Manuel Francisco; Wojdyla, Daniel; Pons-Estel, Guillermo J.; Catoggio, Luis J.; Drenkard, Cristina; Sarano, Judith; Berbotto, Guillermo A.; Borba, Eduardo F.; Sato Inoue, Emilia; Massardo Vega, Loreto